OAB Treatment VL

“Kegels In A Bottle”: Preliminary Results Of A Selective Androgen Receptor Modulator For The Treatment Of SUI - Kenneth M. Peters

Details
(Lecture and Discussion in 14 min.) Kenneth Peters, MD. presents a proof of concept study first discussed at the International Continence Society meeting in September 2017. Ken discusses the background of Enobosarm: and the Biology-Driven Selectivity. He discusses the selective androgen receptor modulators (SARM) biology vs. steroidal androgens and that Enobosarm Increases Pelvic Floor Muscle Weig...

Efficacy, Safety and Health-related Quality of Life of Repeat OnabotulinumtoxinA for OAB and UI - David Sussman

Details
Interim Analysis of Long-term Efficacy, Safety and Health-related Quality of Life of Repeat OnabotulinumtoxinA in the Treatment of Overactive Bladder and Urinary Incontinence David O. Sussman, DO, FACOS Clinical Associate Professor, Department of Surgery Division of Urology, Rowan University Section Head, Female Urology and Voiding Dysfunction Chief of Urology, Kennedy Health System Bibliographica...

Ann Gormley on Diagnosis and Treatment of OAB (Non-neurogenic) in Adults - AUA/SUFU Guideline: An Update

Details
Diagnosis and Treatment of Overactive Bladder (Non-neurogenic) in Adults: AUA/SUFU Guideline - An Update E. Ann Gormley, MD Dartmouth-Hitchcock Medical Center Click HERE to view the Diagnosis & Treatment Algorithm BIOGRAPHY E. Ann Gormley, MD, is Professor of Surgery (Urology) and the program director of the Urology Residency at Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire. Dr. Gor...

Developing an Internationally Applicable Service Specification for Continence Care - Diane Newman

Details
ICS 2014 - Developing an Internationally Applicable Service Specification for Continence Care Diane K. Newman, DNP, ANP-BC, FAAN Click HERE to read the abstract

Practical Aspects of Administration of OnabotulinumtoxinA (Botox®) in the Treatment of OAB

Details
Practical Aspects of the Administration of OnabotulinumtoxinA (Botox ® ) in the Treatment of Overactive Bladder (OAB) In this presentation, Eric Rovner, MD discusses the clinical and practical aspects of using onabotulinumtoxinA (Botox ® ), an option for the management of OAB in adult patients who have an inadequate response or who are intolerant to oral medications. The benefits of treating OAB s...

OnabotulinumtoxinA Treatments Provide Improvements in OAB Patients

Details
AUGS/IUGA 2014 - Repeat Treatments with OnabotulinumtoxinA Provide Long-term Improvements in Symptoms of Overactive Bladder in Female Patients with Urinary Incontinence who are Inadequately Managed by an Anticholinergic Tomasz Rechberger, MD Medical University of Lublin, Poland